Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives D. W. FryJ. L. ShillisW. R. Leopold Preclinical Studies Pages: 3 - 10
Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivatives Dominique BronPierre DodionPierre Stryckmans Preclinical Studies Pages: 11 - 16
Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-0-methyl-doxorubicin Franco ZuninoBrunella BarbieriFranco Quadrifoglio Preclinical Studies Pages: 17 - 23
Comparison of the colony forming ability and invasive potential of six primate cell lines treated with retinoic acid Tatsuyoshi SaigaDale E. WierengaJohn C. Petricciani Preclinical Studies Pages: 25 - 29
Phase I study of oral idarubicin given with a weekly schedule P. DodionC. FinetY. Kenis Clinical Studies Pages: 31 - 38
Phase II trial with oral idarubicin in advanced breast cancer Massimo LopezLuigi Di LauroNicola Di Pietro Clinical Studies Pages: 39 - 42
Novantrone for childhood malignant solid tumors C. B. PrattT. J. ViettiR. B. Patterson Clinical Studies Pages: 43 - 48
Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma William P. McGuireJohn A. BlessingHerbert J. Buchsbaum Clinical Studies Pages: 49 - 52
A phase II study of dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in advanced malignant melanoma James C. ArseneauDavid A. SchoenfeldErnest C. Borden Clinical Studies Pages: 53 - 56
High dose AZQ in renal cancer Ronald L. StephensRobert KirbyRobert M. O'Bryan Clinical Studies Pages: 57 - 59
Regional fibrosis after intraperitoneal administration of mafosfamide John D. RobertsRobert A. NewmanMiles P. Hacker Clinical Studies Pages: 61 - 65
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response William J. MoriconiMilan SlavikSarah Taylor Reviews Pages: 67 - 84